MedPath

Ketanserin

Generic Name
Ketanserin
Drug Type
Small Molecule
Chemical Formula
C22H22FN3O3
CAS Number
74050-98-9
Unique Ingredient Identifier
97F9DE4CT4
Background

Ketanserin has been investigated for the treatment of Septic Shock, Severe Sepsis, and Diabetic Foot Ulcer.

Clinical Trials
Related News

Effect of Ketanserin After LSD Administration

First Posted Date
2020-09-22
Last Posted Date
2021-10-21
Lead Sponsor
University Hospital, Basel, Switzerland
Target Recruit Count
24
Registration Number
NCT04558294
Locations
🇨🇭

Clinical Pharmacology & Toxicology, University Hospital Basel, Basel, Switzerland

Ketanserin Effects on Peripheral Temperature and Lactate

Phase 4
Conditions
Critical Illness
Interventions
Other: Placebo
First Posted Date
2018-08-24
Last Posted Date
2018-08-24
Lead Sponsor
Onze Lieve Vrouwe Gasthuis
Target Recruit Count
120
Registration Number
NCT03646318

The Neurobiological Effect of 5-HT2AR Modulation

Phase 1
Recruiting
Conditions
Basic Science
Interventions
First Posted Date
2017-09-21
Last Posted Date
2024-12-16
Lead Sponsor
Gitte Moos Knudsen
Target Recruit Count
200
Registration Number
NCT03289949
Locations
🇩🇰

Neurobiology Research Unit, Rigshospitalet, Copenhagen, Denmark

Efficacy of Pirfenidone Plus MODD in Diabetic Foot Ulcers

Phase 1
Completed
Conditions
Diabetic Foot Ulcer
Interventions
First Posted Date
2015-12-17
Last Posted Date
2015-12-17
Lead Sponsor
University of Guadalajara
Target Recruit Count
60
Registration Number
NCT02632877
Locations
🇲🇽

Molecular Biology and Gene Therapy Institute, Guadalajara, Jalisco, Mexico

🇲🇽

Hospital Valentín Gómez Farías, Zapopan, Jalisco, Mexico

The Role of 5-HT2A Receptor in the Perception of Self and Personal Meaning in Healthy Volunteers

Not Applicable
Completed
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2015-05-21
Last Posted Date
2016-02-01
Lead Sponsor
Psychiatric University Hospital, Zurich
Target Recruit Count
25
Registration Number
NCT02451072
Locations
🇨🇭

Center for Psychiatric Research, Department of Psychiatry, Psychotherapy and Psychosomatic, Psychiatric Hospital, University of Zurich, Zurich, Switzerland

The Effect of Ketanserin on the Microcirculation in Sepsis

Phase 3
Completed
Conditions
Septic Shock
Severe Sepsis
Interventions
First Posted Date
2011-04-06
Last Posted Date
2014-05-09
Lead Sponsor
Medical Centre Leeuwarden
Target Recruit Count
10
Registration Number
NCT01329887
Locations
🇳🇱

Medical Centre Leeuwarden, Leeuwarden, Netherlands

Fenoldopam and Ketanserin for Acute Kidney Failure Prevention After Cardiac Surgery

Phase 3
Terminated
Conditions
Acute Renal Failure
Interventions
Drug: placebo
First Posted Date
2007-11-12
Last Posted Date
2016-11-15
Lead Sponsor
Medical University of Gdansk
Target Recruit Count
60
Registration Number
NCT00557219
Locations
🇵🇱

Department of Cardiac Anesthesiology, Medical University of Gdańsk, Gdańsk, Poland

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy